Phototherapy treatment for long-term COVID-19 patients
This project aims to validate a UVB phototherapy protocol for treating long-COVID symptoms through a clinical trial, offering a non-invasive solution to alleviate patient suffering globally.
Projectdetails
Introduction
As the number of COVID-19 cases grows worldwide, so does the number of those suffering from clinical parameters that last weeks to months post-initial recovery, termed long-COVID. Recent studies indicate that as much as 36.55% of survivors exhibit long-lasting symptoms (e.g., weight loss, chest pain, cognitive and memory disorders, breathlessness), resulting in an estimated ~157 million long-COVID adult patients worldwide to date. Clearly, this growing health problem represents a modern global medical challenge.
Knowledge Gap
This challenge is compounded by a knowledge gap regarding the causes and prevalence of long-COVID, leaving no effective treatments. As noted by The Lancet: “The scientific and medical communities must collaborate … and find effective treatments.”
Proposed Solution
Based on findings from my ERC grant, supported by other COVID-related reports, I propose to validate a UVB radiation (phototherapy) protocol for the treatment of long-COVID patients. Our findings indicate that phototherapy induces an immunological shift that counters that of the COVID phenotype:
- From T helper (Th) 1 cells, which stimulate inflammation and cell-mediated immunity,
- To Th2 cells, which promote humoral immunity.
Expected Outcomes
Phototherapy is also expected to address a range of reported respiratory, cardiovascular, neurological, endocrine, and metabolic long-COVID symptoms.
Clinical Trial and Collaboration
Our PoC entails both validating the proposed treatment via a clinical trial, through a strong collaborative framework with Maccabi Healthcare Services, Israel’s second largest HMO, and conducting pre-commercialization steps to enable quick, easy dissemination on the global stage.
Value Proposition
Taken together, our value proposition is an effective, non-invasive, simple long-COVID treatment that can be implemented through already established phototherapy clinics worldwide. This approach offers immediate relief to long-COVID patients while simultaneously reducing the health and financial burden of severely overburdened health systems.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-9-2023 |
Einddatum | 28-2-2026 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- TEL AVIV UNIVERSITYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Mission Remission: Integrated characterization of the HIV Reservoir and Host Immune Responses after Antibody-ImmunotherapyThis project aims to investigate the mechanisms behind higher rates of HIV remission through antibody-based immunotherapy to develop effective, drug-free HIV cure strategies. | ERC Starting... | € 1.498.130 | 2024 | Details |
Transcranial photobiomodulation for motion sickness mitigationThe PhotoMod project aims to develop a commercial wearable device using transcranial photobiomodulation to mitigate cyber and motion sickness by targeting the human vestibular network. | ERC Proof of... | € 150.000 | 2025 | Details |
Reversing vaccine hypo-responsivenessThe project aims to understand and reverse vaccine hypo-responsiveness across populations by investigating immunological and metabolic factors, ultimately improving vaccine efficacy globally. | ERC Advanced... | € 2.372.681 | 2022 | Details |
AIDA: Allergy Immunotherapy based on Designed AllergensDevelop a multi-allergen immunotherapy to accelerate tolerance and minimize side effects for patients suffering from both respiratory and food allergies. | ERC Proof of... | € 150.000 | 2023 | Details |
Moving cell-based immunotherapies to fight bacterial lung infections into the clinicsiMAClung aims to develop an immune cell-based therapy using induced pluripotent stem cell-derived macrophages to combat bacterial airway infections and enhance lung regeneration. | ERC Proof of... | € 150.000 | 2024 | Details |
Mission Remission: Integrated characterization of the HIV Reservoir and Host Immune Responses after Antibody-Immunotherapy
This project aims to investigate the mechanisms behind higher rates of HIV remission through antibody-based immunotherapy to develop effective, drug-free HIV cure strategies.
Transcranial photobiomodulation for motion sickness mitigation
The PhotoMod project aims to develop a commercial wearable device using transcranial photobiomodulation to mitigate cyber and motion sickness by targeting the human vestibular network.
Reversing vaccine hypo-responsiveness
The project aims to understand and reverse vaccine hypo-responsiveness across populations by investigating immunological and metabolic factors, ultimately improving vaccine efficacy globally.
AIDA: Allergy Immunotherapy based on Designed Allergens
Develop a multi-allergen immunotherapy to accelerate tolerance and minimize side effects for patients suffering from both respiratory and food allergies.
Moving cell-based immunotherapies to fight bacterial lung infections into the clinics
iMAClung aims to develop an immune cell-based therapy using induced pluripotent stem cell-derived macrophages to combat bacterial airway infections and enhance lung regeneration.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance. | EIC Transition | € 1.881.875 | 2023 | Details |
Next Generation Glioma Treatments using Direct Light TherapyGlioLighT aims to revolutionize glioma treatment by developing Direct Light Therapy (DLT) for targeted ROS generation, enhancing efficacy and safety while eliminating the need for toxic photosensitisers. | EIC Pathfinder | € 2.219.087 | 2024 | Details |
Artificial Intelligence Chrono SunglassesHet project ontwikkelt AI Chrono Zonnebrillen voor Parkinson-patiënten om lichttherapie te optimaliseren en hun kwaliteit van leven te verbeteren. | Mkb-innovati... | € 350.000 | 2021 | Details |
Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumoursPadeliporfin-VTP therapy offers a minimally invasive treatment for UTUC by using laser-activated photosensitizers to eliminate tumors while preserving organ function, aiming for regulatory approval and market entry. | EIC Accelerator | € 2.498.730 | 2024 | Details |
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkankerDe ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren. | Mkb-innovati... | € 20.000 | 2020 | Details |
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.
Next Generation Glioma Treatments using Direct Light Therapy
GlioLighT aims to revolutionize glioma treatment by developing Direct Light Therapy (DLT) for targeted ROS generation, enhancing efficacy and safety while eliminating the need for toxic photosensitisers.
Artificial Intelligence Chrono Sunglasses
Het project ontwikkelt AI Chrono Zonnebrillen voor Parkinson-patiënten om lichttherapie te optimaliseren en hun kwaliteit van leven te verbeteren.
Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours
Padeliporfin-VTP therapy offers a minimally invasive treatment for UTUC by using laser-activated photosensitizers to eliminate tumors while preserving organ function, aiming for regulatory approval and market entry.
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker
De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.